Dasher Neuroscience proudly participated in the World Parkinson Congress 2026 in Phoenix, joining the global Parkinson’s disease community for a week of scientific exchange, collaboration, and meaningful dialogue.

At our exhibition booth, we were pleased to engage with researchers, clinicians, advocacy groups, patients, families, and industry partners, and to share our latest progress in neurodegenerative disease research and therapeutic development. We sincerely thank everyone who visited our booth and took the time to exchange ideas and insights with our team.

A key highlight of the week was our hosted Cocktail Social, featuring a distinguished speaker program. We extend our sincere thanks to all speakers for sharing their perspectives and experiences:

Clyde Campbell, Founder of the Shake It Up Australia Foundation

Group photo with the MUFG team

Following a rigorous evaluation by a committee of over 25 top international Parkinson’s experts, Dasher Neuroscience’s AI drug for neurodegenerative diseases was selected for the iLCT program, a joint initiative by the UK Parkinson’s research charity Cure Parkinson’s and the US-based Van Andel Institute (VAI). Now officially included in the Priority List for Parkinson’s disease clinical development, the drug is poised to potentially receive clinical trial funding from Cure Parkinson’s in the future.

Since 2012, the iLCT program has invested £10.3 million (approximately NT$438 million) to support the development of various Parkinson’s therapies and diagnostics, recruiting over 4,700 Parkinson’s patients globally for related clinical trials. The program has completed 21 Parkinson’s clinical trials, with another 20 currently underway.

Being selected for iLCT Parkinson’s priority list highlights the novelty, therapeutic potential, and R&D capabilities of its AI-developed therapy for neurodegenerative diseases, while also placing the company on the global Parkinson’s research map.

Following this milestone, Dasher Neuroscience has initiated strategic collaborations with the Shake It Up Australia Foundation and the Movement Disorders Society of Australia and New Zealand Clinical Trials Network (MDSANZ CTN). Through this partnership, the Shake It Up Australia Foundation is expected to provide funding support for Dasher Neuroscience’s planned clinical trials in Australia.

Jane Tseng, CEO of Dasher Neuroscience, stated that the Shake It Up Australia Foundation is the largest non-governmental organization funding Parkinson’s research in Australia. The foundation collaborates with the Michael J. Fox Foundation (MJFF), the world’s largest private funder of Parkinson’s research, to advance promising Parkinson’s therapies into clinical trials. To date, the Shake It Up Australia Foundation has provided funding to 23 research institutions and supported up to 79 research projects in Australia, with total grants exceeding AU$30 million (approximately NT$680 million).

Moreover, through close collaboration with the MDSANZ CTN, Dasher Neuroscience is expected to leverage its extensive network of hospitals and research centers across Australia and New Zealand. This will facilitate large-scale, cross-regional matching of patient and physician resources, enhance patients’ access to clinical trials for movement disorders, and accelerate trial execution.

Jane Tseng noted that the company’s AI-developed therapy for neurodegenerative diseases has consecutively received recognition and support from iLCT, the Shake It Up Australia Foundation, and the Movement Disorders Society of Australia and New Zealand Clinical Trials Network (MDSANZ CTN). This strong backing will significantly help the company connect with leading Parkinson’s disease experts worldwide and accelerate the implementation of clinical trials at prominent medical centers across multiple countries. At the same time, it reflects Taiwan’s emergence into the global first-tier of Parkinson’s drug development.

About YODA Pharmaceuticals Inc. (YODA-KY)

YODA–KY (7829), listed on the Emerging Stock Board on June 3, 2025, is a biopharmaceutical company focused on AI-driven drug discovery and the development of therapies for CNS disorders.

The company’s flagship drug, YA-101, is initially targeting multiple system atrophy (MSA) and is currently in Phase II clinical trials. YA-101 has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation (ODD) in the U.S., Japan, and the EU. Additionally, YA-102,  for Parkinson’s disease, is under development. The company is also advancing two preclinical drug candidates: YA-201 for Alzheimer’s disease and YA-301 for schizophrenia.

Committed to addressing significant unmet medical needs, YODA–KY focuses on providing innovative, safe, and effective therapeutic solutions. For more information, please visit: www.dasherneuroscience.com.

YA-101 was granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of multiple system atrophy (MSA) in July 2022 and received Fast Track Designation from the FDA in December 2025. In the same month, YA-101 was also designated as an orphan drug for MSA by Japan’s Ministry of Health, Labour and Welfare (MHLW). The recent Orphan Drug Designation by the European Medicines Agency (EMA) further underscores YA-101’s clinical potential in addressing a significant unmet medical need and supports the company’s global clinical development and market strategy.

YA-101 is a New Chemical Entity (NCE) specifically designed to treat neurodegenerative diseases, primarily by inhibiting neuroinflammation and enhancing neuroplasticity to improve disease outcomes. The drug completed its Phase I clinical trial in Australia among healthy adult subjects in 2024. Currently, YA-101 is undergoing Phase II clinical trials for patients with MSA. The study is randomized, double-blind, placebo-controlled, and conducted simultaneously across multiple clinical sites in the United States, Japan, and Taiwan. According to the trial plan, full subject enrollment is expected to be completed in 2026.

In addition, YODA-KY completed a cash capital increase on the 5th of this month, raising NT$920 million, which has been fully received. The capital increase is based on a record date of January 5, 2026. The proceeds will strengthen the company’s operating capital and support the continued advancement of clinical trials and R&D programs for YA-101 and other investigational drugs.

Jane Tseng, CEO of YODA-KY, stated: “YA-101 has consecutively received regulatory recognition in the U.S., Japan, and the EU, highlighting the company’s capabilities and commitment in international new drug development. With the completion of this month’s cash capital increase, we are fully committed to advancing clinical development and addressing the unmet medical needs of patients with neurodegenerative central nervous system disorders.”

About Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA) is a rare, rapidly progressive, and fatal neurodegenerative disease that affects the autonomic nervous system and leads to a decline in motor function. Patients frequently experience severe orthostatic hypotension, urinary dysfunction, unsteady gait, ataxia, speech impairment, and cognitive decline, which severely impact their quality of life. Current treatment approaches primarily focus on symptomatic relief, such as dopamine replacement therapy and autonomic nervous system modulators; however, their efficacy is limited, and there are currently no approved drugs on the market for MSA. The global prevalence of MSA is approximately 5 cases per 100,000 people. The number of patients in the United States ranges from approximately 15,000 to 50,000, while Japan has about 12,000 patients, representing a prevalence rate higher than the global average.

About YODA Pharmaceuticals Inc. (YODA-KY)

YODA-KY (7829), listed on the Emerging Stock Board on June 3, 2025, is a biopharmaceutical company dedicated to AI-driven drug discovery, with a primary focus on treatments for central nervous system (CNS) disorders. Its flagship drug candidate, YA-101, is currently in Phase II clinical trials for its lead indication, Multiple System Atrophy (MSA). Driven by a mission to address significant unmet medical needs, YODA -KY is committed to providing innovative, safe, and effective therapeutic solutions. For more information, please visit the company’s website at www.dasherneuroscience.com.

YA-101 is a New Chemical Entity (NCE) specifically designed to treat neurodegenerative diseases, primarily by inhibiting neuroinflammation and enhancing neuroplasticity to improve disease outcomes. The drug received Orphan Drug Designation (ODD) from the US FDA for Multiple System Atrophy in 2022, completed its Phase I clinical trial in Australia among healthy adult subjects in 2024, and was granted Fast Track Designation by the U.S. FDA for the treatment of MSA in December 2025. Currently, YA-101 is undergoing Phase II clinical trials for patients with MSA. The study is randomized, double-blind, placebo-controlled, and conducted simultaneously across multiple clinical sites in the United States, Japan, and Taiwan. According to the trial plan, full subject enrollment is expected to be completed in 2026.

Jane Tseng, CEO of YODA-KY, stated: “YA-101 has consecutively received regulatory recognition in the U.S. and Japan, reflecting the company’s growing development capabilities and international standing in new drug development. Japan represents a key market with a relatively large patient population for multiple system atrophy and a well-established healthcare system. We are pleased to have obtained this designation, which supports market exclusivity, and we will continue to advance clinical trials and strengthen our international presence. The company remains focused on innovative therapies for central nervous system disorders, aiming to provide patients with new treatment options and accelerate the global development of novel drugs.”

About Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA) is a rare, rapidly progressive, and fatal neurodegenerative disease that affects the autonomic nervous system and leads to a decline in motor function. Patients frequently experience severe orthostatic hypotension, urinary dysfunction, unsteady gait, ataxia, speech impairment, and cognitive decline, which severely impact their quality of life. Current treatment approaches primarily focus on symptomatic relief, such as dopamine replacement therapy and autonomic nervous system modulators; however, their efficacy is limited, and there are currently no approved drugs on the market for MSA. The global prevalence of MSA is approximately 5 cases per 100,000 people. The number of patients in the United States ranges from approximately 15,000 to 50,000, while Japan has about 12,000 patients, representing a prevalence rate higher than the global average.

About YODA Pharmaceuticals Inc. (YODA-KY)

YODA-KY (7829), listed on the Emerging Stock Board on June 3, 2025, is a biopharmaceutical company dedicated to AI-driven drug discovery, with a primary focus on treatments for central nervous system (CNS) disorders. Its flagship drug candidate, YA-101, is currently in Phase II clinical trials for its lead indication, Multiple System Atrophy (MSA). Driven by a mission to address significant unmet medical needs, YODA -KY is committed to providing innovative, safe, and effective therapeutic solutions. For more information, please visit the company’s website at www.dasherneuroscience.com.

YA-101 is a New Chemical Entity (NCE) specifically designed to treat neurodegenerative diseases, primarily by inhibiting neuroinflammation and enhancing neuroplasticity to improve disease outcomes. The drug received Orphan Drug Designation (ODD) from the US FDA for Multiple System Atrophy in 2022 and completed its Phase I clinical trial in Australia among healthy adult subjects in 2024. Currently, YA-101 is undergoing Phase II clinical trials for patients with MSA. The study is randomized, double-blind, placebo-controlled, and conducted simultaneously across multiple clinical sites in the United States, Japan, and Taiwan. According to the trial plan, full subject enrollment is expected to be completed in 2026.

Jane Tseng, CEO of YODA-KY, stated: “Receiving FDA Fast Track Designation for YA-101 is a major encouragement for our R&D team. It facilitates closer communication and discussion with the FDA, accelerating the overall drug approval process. Currently, there are no FDA-approved therapies for MSA. YA-101 has the potential to improve patients’ lives truly. This designation strengthens our focus on advancing the program, bringing hope to patients while demonstrating the company’s continued growth and capabilities.”

About Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA) is a rare, rapidly progressive, and fatal neurodegenerative disease that affects the autonomic nervous system and leads to a decline in motor function. Patients frequently experience severe orthostatic hypotension, urinary dysfunction, unsteady gait, ataxia, speech impairment, and cognitive decline, which severely impact their quality of life. Current treatment approaches primarily focus on symptomatic relief, such as dopamine replacement therapy and autonomic nervous system modulators; however, their efficacy is limited, and there are currently no approved drugs on the market for MSA. The global prevalence of MSA is approximately 5 cases per 100,000 people. The number of patients in the United States ranges from approximately 15,000 to 50,000, while Japan has about 12,000 patients, representing a prevalence rate higher than the global average.

About YODA Pharmaceuticals Inc. (YODA-KY)

YODA-KY (7829), listed on the Emerging Stock Board on June 3, 2025, is a biopharmaceutical company dedicated to AI-driven drug discovery, with a primary focus on treatments for central nervous system (CNS) disorders. Its flagship drug candidate, YA-101, is currently in Phase II clinical trials for its lead indication, MSA. Driven by a mission to address significant unmet medical needs, YODA -KY is committed to providing innovative, safe, and effective therapeutic solutions. For more information, please visit the company’s website at www.dasherneuroscience.com.

Focusing on the use of artificial intelligence (AI) to develop new drugs for the central nervous system, Cayman Islands-based Yoda Pharmaceuticals Inc. (hereinafter referred to as YODA-KY, stock code 7829) announced today (27) that its subsidiary, Dasher Neuroscience Inc. (formerly Yoda therapeutics Inc.), has completed the signing of a Memorandum of Understanding (MOU) with Helse Bergen HF, Haukeland University Hospital in Bergen, Norway. Both parties will engage in in-depth collaboration to advance an AI-driven novel drug into the HYDRA platform trial. The therapy is expected to become the first from Taiwan to enter one of the world’s two largest platform trials for Parkinson’s disease. YODA-KY aims to leverage this opportunity to connect with a clinical network of 14 hospitals in Norway, proactively positioning itself to advance into global clinical trials in the fourth quarter of 2026. This initiative will contribute to the development of the international clinical research ecosystem for Parkinson’s disease and marks a significant milestone in the company’s expansion into Europe.

This MOU will foster information exchange between the two parties in Parkinson’s disease research and therapeutics, enhance public awareness of the disease, and pave the way for joint participation in the HYDRA clinical trial.

HYDRA, a phase III efficacy platform trial, is one of the world’s largest platform trials for Parkinson’s disease (PD). Initiated by Neuro-SysMed, a Centre for Clinical Treatment Research Center in Norway, the initiative aims to accelerate breakthroughs in the field of PD by testing multiple disease-modifying therapies (DMTs) in parallel that can potentially alter the course of Parkinson’s disease.

HYDRA features highly integrated clinical resources, an extensive patient recruitment network, and a standardized data infrastructure. The platform trial is expected to enroll 800 participants across 14 hospitals covering all four health regions of Norway to evaluate the efficacy of three Parkinson’s disease therapies in slowing disease progression.

Notably, the trial adopts a multi-arm, multi-stage (MAMS) adaptive design, enabling treatments to be discontinued early while reallocating patients to more promising treatment arms. This approach is expected to shorten trial timelines and enhance overall clinical trial efficiency. The study is scheduled to commence in the fourth quarter of 2026, with efficacy results anticipated within five years[1].

HYDRA is led by Dr. Geir Olve Skeie (Coordinating Investigator) and Study Director Charalampos Tzoulis, who is Professor of Neurology and Neurogenetics at the University of Bergen and Senior Consultant at Haukeland University Hospital.

Prof. Tzoulis noted that in addition to adopting the gold-standard Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), HYDRA also integrates objective measures such as digital monitoring and molecular biomarkers to assess long-term drug efficacy and inform personalized treatment strategies.

Tzoulis further highlighted that HYDRA is supported by funding from KLINBEFORSK, the Regional Health Authority of Western Norway, the Research Council of Norway, Neuro-SysMed, the Norwegian Parkinson Association, and leading medical centers. Backed by strong financial support and an extensive clinical network, HYDRA is well-positioned for patient recruitment and to advance treatment development for Parkinson’s disease.

YODA–KY CEO Jane Tseng stated that initiating a collaboration with Haukeland University Hospital marks a critical milestone for the company’s entry into the HYDRA platform trial and its expansion into global and European markets. Through the innovative “shared placebo group” trial design, more participants will have the opportunity to access investigational drugs, accelerating the progress of clinical trials. This approach can enable Taiwanese novel drug candidates to directly connect with Europe’s leading research centers, helping establish a robust international ecosystem for Parkinson’s disease clinical research.

Tseng also emphasized that α-synuclein–related disorders are progressive, highly disabling neurodegenerative diseases with no current treatment options, including Parkinson’s disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Dasher Neuroscience is committed to developing novel therapies for α-synuclein–related neurodegenerative diseases and advancing global clinical trial initiatives, aiming to bring innovative treatments to patients.

About YODA–KY (Cayman Islands)

YODA–KY (7829), listed on the Emerging Stock Board on June 3, 2025, is a biotech pharmaceutical company focused on AI-driven drug discovery and the development of therapies for central nervous system disorders.

The company’s flagship drug, YA-101, is initially targeting multiple system atrophy (MSA) and is currently in Phase II clinical trials. YA-101 has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation (ODD) in the U.S., Japan, and the EU. Additionally, YA-102, for Parkinson’s disease, is under development. The company is also advancing two preclinical drug candidates: YA-201 for Alzheimer’s disease and YA-301 for schizophrenia.

Committed to addressing unmet medical needs, YODA–KY focuses on providing innovative, safe, and effective therapeutic solutions. For more information, please visit: https://dasherneuroscience.com

Note: For more information on the HYDRA international platform trial in Norway, see:

[1] https://www.helse-bergen.no/en/neuro-sysmed-english/clinical-studies-at-neuro-sysmed/parkinsons–clinical-studies/HYDRA/